2,851
+5.59%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Heartseed
Its shares trade on Tokyo Stock Exchange under the ticker 219A.T. It has been listed since 30 July 2024. In the fiscal year to 31 October 2025, it reported revenue of ¥3.03bn and net income of ¥163.4m. At that date it held total assets of ¥8.14bn and shareholders' equity of ¥7.57bn.
Heartseed Inc is a JP-based company operating in Biotechnology industry. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2024-07-30. Heartseed Inc is a Japan-based company engaged in research and development of regenerative medicine products. The firm has established cardiac regenerative medicine, a therapy in which microtissue (cardiomyocytes) derived from iPS cells are transplanted into the heart, and conducts business activities for patients with severe heart failure. Target diseases include dilated cardiomyopathy (DCM), old myocardial infarction (OMI), and dilated-phase hypertrophic cardiomyopathy (D-HCM). Except the pipeline's leading cardiac treatment HS-001 (administration of regenerated myocardium derived from allogeneic iPS cells to the myocardium), the Company also conducts research into the creation of myocardium using autologous iPS cells that do not pose immune rejection reactions and iPS cells with HLA knockout.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Jul 2024
- Employees
- 39
- Website
- heartseed.jp ↗
Leadership
Pay as last reported
- Mr. Keiichi FukudaPresident, Chief Executive Officer, Founder, Representative Director
- Mr. Mutsuki TakanoChief Financial Officer, Director, since 2020
- Mr. Kikuo YasuiChief Operating Officer, Director, since 2019
- Mr. Tatsuyoshi HiranoChief Administrative Officer, Director, since 2021
- Dr. Takehiko KanekoDirector, Chief Medical Officer, Chief Director of Research and Development, since 2020
- Dr. Toshiharu FurukawaIndependent Director
- Mr. Yutaro KasaiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Heartseed Inc's HS-001 targets severe heart failure with regenerative medicine using allogeneic iPS cells.
- The company focuses on cardiac regenerative medicine for diseases like DCM and OMI in Japan.
- Heartseed Inc's research includes autologous iPS cells to avoid immune rejection reactions.
Weaknesses
- Heartseed Inc has only 39 employees, limiting its operational capacity.
- The company's IPO on 30 July 2024 indicates recent market entry.
- Heartseed Inc's pipeline is centered on cardiac regenerative medicine without diversification.
Opportunities
- Expanding regenerative medicine applications in Japan's aging population.
- Growing demand for cardiac treatments in the Health Care sector.
- Potential for international collaboration in biotechnology research.
Threats
- Competition from established biotechnology firms in Japan.
- Regulatory challenges in the Health Care industry for new therapies.
- High costs associated with regenerative medicine research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.